Prof Hellmich takes us through “What is new?” In ANCA #vasculitis A tour de force in management strategies and, continuing a theme of #EULAR2024, ends with a study suggesting the potential of #CAR-T! @RheumNow https://t.co/K3dDqZhUvD

What is better for #Rx of #osteoporosis? #Denosumab or ##Zoledronic acid? #Prolia compared to #Aclasta Giant admin US data of 125,000 Rx niaive women with #OP ▶️Prolia has LESS fractures! POS0583 #EULAR2024 @eular_org @RheumNow https://t.co/eo1ny2VIRf

✨ Delighted to be chairing the session on newly diagnosed #RMDs in the PARE programme this afternoon, featuring a fantastic panel of speakers! 👥 Perfect for patients and clinicians alike! 👇🏼 All details below- hope to see you there @RheumNow #EULAR2024 https://t.co/8RmcH8qprJ

What is better in #PsA #psoriatic #arthritis #TNFi or #apremilast #PDE4i #COREVITAS database study in #PsA YOU can guess the answer! 1st line advanced RxTNFi lasts longer - retention Vs PDE4i #EULAR2024 @RheumNow @eular_org POS0990 https://t.co/VmYG6Rj87c

Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3

Discovery in joint and skin disease - PsA Three different clusters #EULAR2024 @RheumNow https://t.co/Nj5HZOVqas

Predicting who will develop ▶️#GCA In #Swedish study with #PMR ⬆️ in HIGH ESR/CRP ⬆️female ⬇️ if hip pain/stiffness Not all sig 1 mo after #prednisone started Only 9% with #polymyalgia #rheumatica developed #GCA ? ⬇️GCA % in PMR over time #POS0411 @eular_org @RheumNow https://t.co/UMhxlYd0Pv

The art of talking about risks with our patients https://t.co/V0JQ1EsbKc https://t.co/GSTbPu0EXZ

The age old question in #inflammatory #arthritis Should you cycle within TNFi class or move on to another MOA in #PsA #psoriatic #arthritis Better retention to go to a IL17i vs another TNFi in observational study comparing the 2 POS0266 #EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9

Can you predict which pts with #PsA #psoriatic #arthritis Will respond to #TNFi #Rx? Well, 🤔 maybe Needs validation and an easy reliable inexpensive biomarker! #EULAR2024 @RheumNow @eular_org POS0992 https://t.co/Ce92561AMO